CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A. Diagnostic Radiopharmaceuticals I-3
B. Therapeutic Radiopharmaceuticals I-4
II. A US & EUROPEAN MARKET REPORT
1. Industry Overview II-1
A Quick Primer II-1
Key Market Trends II-1
Continuous Battle Against Cancer: A Key Driver for Growth II-1
Cancer Statistics: A Grim Prognosis II-1
Business Case for Radiopharmaceuticals Exemplified II-1
Development of Newer Diagnostic Agents to Boost Growth II-2
Demographics & New Applications Offer Opportunities On a Platter II-2
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance II-2
Widespread Awareness Among Practitioners & Patients: The Need
of the Hour II-2
Expansion of Molecular Imaging Platform is Key to Future Growth II-3
Molecular Imaging Agents: A Noteworthy Breakthrough II-3
Growing Demand for PET to Drive Up Demand II-4
Introduction of SPECT/CT & PET/CT: Double Edged Weapons for
Growth II-4
Manufacturers Quick to Take Cue II-5
Promising Developments in Therapeutic Radiopharmaceuticals
Underway II-5
Targeted Peptides & Alpha Emitters: The New Frontiers of
Therapeutic Radiopharmaceuticals II-5
International Collaborations Give a Thumbs Up to Drug
Development II-6
Market Challenges II-6
High Costs of Drug Development Piques Manufacturers II-6
Supply Shortages: A Niggling Cause of Concern II-6
Price Sensitivity & Competition from Alt
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |